Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Eiko LifeSciences Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Umesh More

İcra Kurulu Başkanı

₹600.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.2yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.7yrs
Yönetim Kurulu ortalama görev süresi	4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Umesh More'un ücretlendirmesi Eiko LifeSciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	₹10m
Mar 31 2024	₹600k	n/a	₹8m
Dec 31 2023	n/a	n/a	₹7m
Sep 30 2023	n/a	n/a	₹7m
Jun 30 2023	n/a	n/a	₹8m
Mar 31 2023	₹600k	₹600k	₹8m
Dec 31 2022	n/a	n/a	₹6m
Jun 30 2022	n/a	n/a	₹4m
Mar 31 2022	₹450k	₹450k	₹7m

Tazminat ve Piyasa: Umesh 'nin toplam tazminatı ($USD 7.16K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 42.95K ).

Tazminat ve Kazançlar: Umesh 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Umesh More

3.2yrs

Görev süresi

₹600,000

Tazminat

Mr. Umesh Ravindranath More serves as Additional Executive Director at Eiko LifeSciences Limited (formerly known as Narendra Investments (Delhi) Limited) since November 12, 2020 and also serves as its Whol...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Umesh More	Whole-Time Director	3.2yrs	₹600.00k	Veri yok
Jaid Kojar	Chief Financial Officer	2.7yrs	₹780.00k	0.40% ₹ 3.1m
Chintan Doshi	Company Secretary & Compliance Officer	less than a year	₹94.00k	Veri yok

2.7yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 540204 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Umesh More	Whole-Time Director	3.9yrs	₹600.00k	Veri yok
Laxmikant Kabra	Non-Executive Chairman	11.2yrs	Veri yok	12.37% ₹ 94.1m
Bhavesh Tanna	Non-Executive Non-Independent Director	11.2yrs	Veri yok	3.14% ₹ 23.9m
Kajal Kothari	Non-Executive Independent Director	4.1yrs	Veri yok	Veri yok
Rajkumar Baheti	Non-Executive - Independent Director	3.7yrs	Veri yok	Veri yok
Hasti Doshi	Independent Director	less than a year	Veri yok	Veri yok

4.0yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 540204 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

Eiko LifeSciences Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Eiko LifeSciences Limited, Annual General Meeting, Sep 28, 2024

Insufficient new directors

Eiko Lifesciences Limited Approves Appointment of Company Secretary and Compliance Officer

Eiko LifeSciences Limited, Annual General Meeting, Sep 23, 2023

Eiko Lifesciences Limited Announces Resignation of Nilima Burghate as Company Secretary and Compliance Officer

Eiko LifeSciences Limited Approves Appointment of Nilima A. Burghate as Company Secretary and Compliance Officer

Recent updates

Eiko LifeSciences Limited, Annual General Meeting, Sep 28, 2024

First quarter 2025 earnings released: EPS: ₹0.29 (vs ₹0.10 in 1Q 2024)

Eiko LifeSciences Limited to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings released: EPS: ₹0.73 (vs ₹0.92 in FY 2023)

Eiko LifeSciences Limited to Report Q4, 2024 Results on May 13, 2024

Now 20% overvalued

Now 21% overvalued

Now 22% overvalued

Insufficient new directors

Third quarter 2024 earnings released: EPS: ₹0.24 (vs ₹0.31 in 3Q 2023)

Eiko LifeSciences Limited to Report Q3, 2024 Results on Feb 08, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ₹0.12 (vs ₹0.31 in 2Q 2023)

Eiko Lifesciences Limited Approves Appointment of Company Secretary and Compliance Officer

Eiko LifeSciences Limited, Annual General Meeting, Sep 23, 2023

Eiko Lifesciences Limited Announces Resignation of Nilima Burghate as Company Secretary and Compliance Officer

Eiko LifeSciences Limited Approves Appointment of Nilima A. Burghate as Company Secretary and Compliance Officer

Eiko LifeSciences Limited has completed a Follow-on Equity Offering in the amount of INR 249.48801 million.

New major risk - Shareholder dilution

Whole-time Director recently sold ₹995k worth of stock

First quarter 2024 earnings released: EPS: ₹0.10 (vs ₹0.10 in 1Q 2023)

New minor risk - Share price stability

Eiko LifeSciences Limited to Report Q1, 2024 Results on Jul 11, 2023

Investor sentiment improves as stock rises 19%

Eiko Lifesciences Limited Announces Resignation of Avi Vijaykumar Mundecha as Company Secretary and Compliance Officer

Full year 2023 earnings released: EPS: ₹0.92 (vs ₹0.90 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹0.31 (vs ₹0.07 loss in 3Q 2022)

Eiko LifeSciences Limited to Report Q3, 2023 Results on Jan 17, 2023

Eiko LifeSciences Limited to Report Q2, 2023 Results on Oct 21, 2022

First quarter 2023 earnings released: EPS: ₹0.10 (vs ₹0.64 in 1Q 2022)

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: ₹0.90 (vs ₹1.61 in FY 2021)

Investor sentiment improved over the past week

Eiko LifeSciences Limited, Annual General Meeting, Jun 25, 2022

Eiko LifeSciences Limited, Annual General Meeting, Jun 25, 2022

Full year 2022 earnings released: EPS: ₹0.90 (vs ₹1.61 in FY 2021)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Eiko Lifesciences Limited Announces Chief Financial Officer Changes

Eiko LifeSciences Limited to Report Q3, 2022 Results on Feb 08, 2022

Eiko LifeSciences Limited to Report Q3, 2022 Results on Feb 08, 2022

Company Secretary & Compliance Officer Chintan Doshi has left the company

Narendra Investments (Delhi) Limited (BSE:540204) acquired Manufacturing Unit at MIDC, Badlapur.

Narendra Investments (Delhi) Limited Appoints Rajkumar K Baheti as Additional Independent Director

New 90-day high: ₹37.80

Narendra Investments (Delhi) Limited to Report Q3, 2021 Results on Feb 10, 2021

New 90-day high: ₹35.70

New 90-day high: ₹34.00

Narendra Investments (Delhi) Limited Appoints Umesh More as Additional Executive Director

Narendra Investments (Delhi) Limited to Report Q2, 2021 Results on Nov 12, 2020

Full year earnings released - ₹4.99 loss per share

New 90-day high - ₹38.65

New 90-day high - ₹35.10

Narendra Investments (Delhi) Limited to Report Q1, 2021 Results on Sep 08, 2020

Narendra Investments (Delhi) Limited to Report Q4, 2020 Results on Jun 27, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş